Meridian Bioscience Stock

Meridian Bioscience Operating Cash Flow

The Operating Cash Flow of Meridian Bioscience (VIVO) as of Aug 5, 2026 is 82.36 M USD. In the previous year, Operating Cash Flow was 66.87 M USD — a change of 23.18% (higher).

Operating Cash Flow

82.36 MUSD

YoY

23.18%

Last updated:

Operating Cash Flow of Meridian Bioscience is 2026 82.36 M USD. Operating Cash Flow of Meridian Bioscience was 2025 66.87 M USD. It decreases by 23.18% higher compared to the previous year.
Access this data via the Eulerpool API

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Operating Cash Flow of Meridian Bioscience is 82.36 M USD in 2026.

Operating Cash Flow of Meridian Bioscience changed from 66.87 M USD to 82.36 M USD, representing a 23.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Meridian Bioscience historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Meridian Bioscience

All Key Metrics — Meridian Bioscience